SubscribeLatest 5 articles from heartwire
- Long-term, but small, PASSION and DEDICATION studies raise concern about DES in STEMI
Mar 16, 2010 18:15 EDT - PLATO CABG analysis confuses cardiologists
Mar 16, 2010 17:15 EDT - Patency for radial-artery no better than saphenous-vein grafts at one year
Mar 16, 2010 16:15 EDT - Warfarin genotyping reduces hospitalizations
Mar 16, 2010 16:00 EDT - Finally final? New STICH analysis finds no subset that benefits from ventricular reconstruction
Mar 16, 2010 14:45 EDT
Rosuvastatin in the prevention of venous thromboembolism
Posted May 29, 2009
at 11:45 AM, EDT
by Samuel Goldhaber
What are the implications of the JUPITER trial's landmark findings in preventing venous thromboembolism? A 43% highly significant reduction in incidence and no increased bleeding risk with rosuvastatin 20 mg daily compared with placebo. Where do we go next? And what do we do now in clinical practice?
Please refer to the epublished JUPITER manuscript: Glynn RJ et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; March 29.
Posted by A G G Turpie, Aug 12, 2009
Publié le A G G Turpie, 08.12.2009
Previous postsBillets précédents
Anticoagulation "bridging" for patients with VTE
5 comments5 commentaires |
Posted Feb 26, 2010
at 12:50 PM, EDT by Samuel Publié le 02.26.2010 à 12h50 par Samuel
at 12:50 PM, EDT by Samuel Publié le 02.26.2010 à 12h50 par Samuel
Early anticoagulation associated with reduced mortality for acute pulmonary embolism
No commentsAucun commentaire |
Posted Feb 02, 2010
at 10:55 AM, EDT by Samuel Publié le 02.02.2010 à 10h55 par Samuel
at 10:55 AM, EDT by Samuel Publié le 02.02.2010 à 10h55 par Samuel
Anticoagulation during pregnancy: What are we to do?
No commentsAucun commentaire |
Posted Dec 17, 2009
at 10:30 AM, EDT by Samuel Publié le 12.17.2009 à 10h30 par Samuel
at 10:30 AM, EDT by Samuel Publié le 12.17.2009 à 10h30 par Samuel
Major bleeding predicts mortality in VTE prevention trials
No commentsAucun commentaire |
Posted Dec 08, 2009
at 11:30 AM, EDT by Samuel Publié le 12.08.2009 à 11h30 par Samuel
at 11:30 AM, EDT by Samuel Publié le 12.08.2009 à 11h30 par Samuel
Epidemiology of pulmonary embolism in the US
No commentsAucun commentaire |
Posted Nov 04, 2009
at 02:00 PM, EDT by Samuel Publié le 11.04.2009 à 14h00 par Samuel
at 02:00 PM, EDT by Samuel Publié le 11.04.2009 à 14h00 par Samuel
Also from theheart.org
Blogs I read
Who's Talking
Samuel Z Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA
CommentsCommentaires
Given that there are a plethora of statin trials that have already been conducted, it would seem that, even though VTE may not have been a prespecified endpoint, one could go back to these databases and determine whether similar reductions in VTE were demonstrated versus placebo.
Der Dr Goldhaber,
DVT is a real threat as we know but this is the first time that we have discovered the statins to have a bearing on it.Congratulations to you from India!
Dr Sadasivan.
the Virchow triad:
thrombosis is due to three factors-stasis
-hypercoaguabilité
-hyperviscosity
when you give a cause neuroleptic you demunition stasis by the seimulation nerve in vascular
so it always involve a antiagréguant or heparin with neuroleptics